CF Drug's emotional side effects under the microscope
NCT ID NCT03659214
First seen Nov 20, 2025 · Last updated May 20, 2026 · Updated 19 times
Summary
This study looked at how starting the medication ORKAMBI changes anxiety, depression, quality of life, and treatment adherence in 19 adolescents and young adults (ages 12-20) with cystic fibrosis. Researchers compared those taking ORKAMBI to a similar group not on the drug, using questionnaires to track emotional well-being and daily functioning. The goal was to understand the psychological adjustment that comes with starting a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Pneumology -CRCM - Necker - Enfants maladies Hospital (AP-HP)
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.